Triplet kinase-phosphatase targeting to overcome kinase inhibitor tolerance in brain tumor cells

Oxana V. Denisova¹, Joni Merisaari^{1,2}, Riikka Huhtaniemi¹, Xi Qiao¹, Laxman Yetukuri^{1,3}, Mikael Jumppanen¹, Amanpreet Kaur¹, Mirva Pääkkönen¹, Carina von Schantz-Fant³, Michael Ohlmeyer^{5,6}, Krister Wennerberg^{3,7}, Otto Kauko¹, Raphael Koch⁸, Tero Aittokallio^{3,4,9}, Mikko Taipale¹⁰, Jukka Westermarck^{1,2*}

Affiliations:

¹Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

²Institute of Biomedicine, University of Turku, Turku, Finland

³Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.

⁴Centre for Biostatistics and Epidemiology (OCBE), Faculty of Medicine, University of Oslo, Oslo, Norway.

⁵Icahn School of Medicine at the Mount Sinai, NY, USA.

⁶Atux Iskay LLC, Plainsboro, NJ, USA.

⁷Biotech Research & Innovation Centre, University of Copenhagen, Copenhagen, Denmark.

⁸University Medical Center Goettingen, Goettingen, Germany.

⁹Institute for Cancer Research, Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway.

¹⁰Donnelly Centre, University of Toronto, Toronto, Canada.

*Corresponding author. Email: jukka.westermarck@bioscience.fi

Abstract

Kinase inhibitor tolerance of human glioblastoma is an unmet clinical challenge and a mechanistic enigma. Here, we demonstrate that glioblastoma cell tolerance to multi-kinase inhibition can be reverted by reactivation of Protein Phosphatase 2A (PP2A). To characterize kinase targets of clinical stage multi-kinase inhibitor UCN-01 synergizing with PP2A reactivation, we established a strategy, named Actionable Targets of Multi-kinase Inhibitors (AToMI). AToMI revealed AKT and mitochondrial pyruvate dehydrogenase kinases (PDK1-4) as the co-targets for UCN-01-elicited synthetic lethality with PP2A reactivation. Notably, heterogeneous glioblastoma and medulloblastoma models were tolerant to AKT and PDK1-4 inhibitor monotherapies, and their combinations, but were effectively inhibited by triplet therapy including pharmacological PP2A reactivation. Mechanistically, overcoming the kinase therapy tolerance by the triplet therapy could be explained by combinatorial effects on signaling rewiring between AKT and PDK1-4, decrease in mitochondrial oxidative phosphorylation, and BH3-only protein mediated apoptosis priming. The brain-penetrant triplet combination had a significant *in vivo* efficacy in intracranial glioblastoma and medulloblastoma models. Collectively, we present a generalizable approach to identify actionable co-targets of multi-kinase inhibitors and demonstrate that overcoming of the kinase inhibitor tolerance in brain tumor cells requires triplet targeting of AKT, PDK1-4, and PP2A.

Introduction

Even though kinase inhibitors have revolutionized cancer therapies, most tumors acquire resistance to kinase inhibitors (1,2). Especially in cancer types genetically associated with hyperactivation of kinase pathways, such as human glioblastoma, the clinically observed kinase inhibitor resistance is a mechanistic enigma (3-5). Acquired therapy resistance develops via two phases - first through adaptive development of a drug-tolerant cellular state, and later, stable resistance that often occurs through acquisition of genetic mutations (6). The emerging evidence strongly indicates that the drug-tolerance is initiated rapidly after drug exposure by non-mutational signaling rewiring, often mediated by phosphorylation dependent signaling pathways (7,8). Thereby, characterization of the phosphorylation-dependent signaling rewiring events, and kinases/phosphatases controlling the rewiring, is expected to provide novel approaches for targeting the tumor relapse at its roots (9).

In addition to the development of non-genetic therapy tolerance, lack of target specificity of kinase inhibitors is a major translational challenge (2). Recent studies demonstrate that only a few kinase inhibitors target selectively their intended kinase target, and that the therapeutic effects of many kinase inhibitors are mediated by inhibition of other than their assumed target kinase (10,11). The unselectivity of kinase inhibitors can be employed therapeutically in a case the multi-kinase inhibitor (MKI) (12). Of clinically approved MKIs, sunitinib has an FDA approval for the treatment of gastrointestinal stromal tumors and advanced renal cell carcinoma. Additionally, derivatives of the classical MKI staurosporine (STS), have reached the clinics. Midostaurin (PKC412) is approved for the treatment of FLT3-mutated acute myeloid

leukemia (12), whereas another STS derivative UCN-01 (7-hydroxystaurosporine), was tested in phase II clinical trials in metastatic melanoma and relapsed T-Cell Lymphomas (NCT00082017). However, it is well established that each of these clinically tested STS derivatives inhibit activities of up to 50 kinases with approximately similar efficiency (10,13,14). Further, the STS derivatives are compromised by their pharmacokinetic properties in a case of brain tumors as they do not cross the brain-blood barrier (BBB). Therefore, development of MKIs towards clinical use would benefit from a better understanding of the kinase targets mediating both the therapeutic and potential toxic effects in each disease application. On the other hand, systematic mapping of the kinase targets of each MKI might provide an opportunity for development of novel combination therapy approaches by combining more selective kinase inhibitors targeting only the preferred kinases with more preferential pharmacokinetic and pharmacodynamic profiles. However, generalizable strategies for analysis of actionable MKI targets are currently missing.

Glioblastoma (GB) is the most common primary brain tumor in adults associated with high degree of therapy resistance, tumor recurrence and mortality (5,15). Extensive genome-wide profiling studies have established receptor tyrosine kinase RTK/RAS/PI3K/AKT signaling as one of the core altered pathways contributing to GB disease progression (3,16). AKT pathway fuels aerobic glycolysis (17), and GB cells are notorious for employing aerobic glycolysis in energy production and survival (18,19). However, targeting of these deregulated signaling mechanisms have achieved dismal clinical response rates in GB (4,20,21). Furthermore, disappointing results have been obtained from combination of kinase inhibitors, including also the MKIs (21). In addition to challenges with drug delivery across the BBB with a number of kinase inhibitors, the failure of kinase targeted therapies in GB has been proposed to be

linked to the prevalence of kinase pathway-mediated rewiring mechanisms (21), and general apoptosis-resistance of glioblastoma stem-like cells (GSCs) (15).

Protein phosphatase-2A (PP2A) is a ubiquitous serine/threonine phosphatase. Some PP2A complexes act as tumor suppressors and their inhibition is required for human cell transformation (22,23). PP2A regulates several kinase pathways and drug resistance mechanisms, and PP2A inhibition in cancer cells has been shown to drive broad-range kinase inhibitor resistance (24). PP2A is frequently inactivated in GB by non-genetic mechanisms including overexpression of endogenous PP2A inhibitor proteins such as CIP2A, PME-1, SET and ARPP19 (25-27). We recently published proof-of-concept data that reversal of PME-1-mediated PP2A inhibition strongly sensitized GB cells to several kinase inhibitors, including clinically tested STS derivatives (28). However, the translational value of these results remained questionable as PME-1 was experimentally inhibited by siRNAs and STS molecules that do not cross the BBB. Recently, a series of BBB permeable small molecule activators of PP2A (SMAPs) have been developed (29). However, their effects on kinase inhibitor resistance in GB has not yet been addressed.

To leverage on the therapeutic potential of combination of MKIs with pharmacological PP2A reactivation for GB therapy (28), we established a generalizable multi-step strategy for characterization of Actionable Targets of Multi-kinase Inhibitors (AToMI). The results identify AKT and pyruvate dehydrogenase kinases (PDK1-4) as the targets of MKI UCN-01 in drug-induced synthetic lethality (SL)(30) in combination with PP2A reactivation. As a translationally relevant outcome, we demonstrate that triplet targeting of AKT, PDK and PP2A induced robust synergistic cell death across heterogeneous GB and medulloblastoma (MB) cell lines,

118 and resulted in significant *in vivo* therapeutic effects on intracranial tumor models of GB and
 119 MB. Mechanistically, we identify a role for PP2A in regulating mitochondrial metabolism and
 120 blunting therapy-induced signaling rewiring. Collectively, these results support the clinical
 121 observations that combinations of kinase inhibitors alone are not sufficient for overcoming
 122 kinase inhibitor therapy tolerance in brain cancers, but indicate that this can be achieved by
 123 further combination of kinase inhibitors with pharmacological reactivation of PP2A.

Results

Pharmacological reactivation of PP2A synergizes with a multi-kinase inhibitor UCN-01

Based on our previous data demonstrating that PME-1 effects in GB cell kinase inhibitor resistance are mediated by PP2A (28), we hypothesized that the recently developed PP2A reactivating compounds (SMAPs) (29) could provide a pharmacological approach to induce synthetic lethal (SL) drug interaction (30) with UCN-01 in GB cells (Fig. 1A). To test the hypothesis, we directly compared the synergy with UCN-01 and PP2A reactivation by either PME-1 depletion (31), or SMAP (NZ-8-061) treatment, on colony growth potential of T98G cells. As shown in Fig. 1B, PME-1 depletion (either by siRNA or by CRISPR/Cas9) or NZ-8-061 did not induce any significant growth defect but induced potent SL with UCN-01. The interaction between NZ-8-061 and UCN-01 was dose dependent and observed by using both compounds at concentrations that showed negligible monotherapy activity (Fig. 1C, D, S1A). Validating the particular potential of PP2A reactivation in kinase inhibitor sensitization (9), NZ-8-061 displayed synergistic activity with as low as 0.5-1 μ M concentration, that is approximately 10-fold lower concentrations that has been previously shown to be required for monotherapy effects for the compound (25,32). To rule out that the synergy between NZ-8-061 and UCN-01 would be mediated by any potential non-selective targets of NZ-8-061, we used SMAPs DBK-794 and DBK-1154 derived from dibenzoapine tricyclic family, i.e. chemically different from NZ-8-061 (Fig. 1E). Both DBK-794 and DBK-1154 were originally used to demonstrate direct interaction between SMAPs and PP2A, and for mapping of their interaction region (32). Importantly, these chemically diverse PP2A reactivators all resulted

in identical drug interaction with UCN-01 (Fig. 1C, D, F, S1B). Together with identical synergy observed by genetic PP2A reactivation (Fig. 1B) (28), and induction of synergy with non-toxic low micromolar SMAP concentration (Fig. 1D), the use of SMAPs with different chemistry mitigate concerns that the SMAP effects would be related to potential non-selective effects reported using toxic (10-30 μ M) concentrations of NZ-8-061 (a.k.a DT-061) (33). Induction of caspase 3/7 activity indicated that the mode of cell death by SMAP+UCN-01 combination was apoptosis (Fig. 1G), and the drug interaction was validated in multiple GB cell lines (Fig. 1H, S1B). Importantly, synergy between UCN-01 and NZ-8-061 was not observed in non-cancerous fibroblasts providing evidence for cancer selectivity of the drug interaction (Fig. S1D). The synergistic drug interaction in GB cells was also seen in hypoxic environment, which is a common resistance mechanism in GB (Fig. S1C).

Figure 1. PP2A reactivation and UCN-01 exert a synergistic effect in GB. **A)** Schematic illustrating PP2A reactivation predisposed to MKI-induced synthetic lethality in GB. **B)** Representative images of colony formation assay in T98G cells under PME-1 siRNA-mediated depletion, PME-1 KO or NZ-8-061 treatment. Cells were treated with 25 nM UCN-01 (UCN) or left untreated (NT). Western blot analysis of PME-1 depletion or KO (lower panel). **C)** Viability of T98G cells treated with increasing concentration of NZ-8-061 either alone or in combination with 25 nM UCN-01 (UCN) for 72 h. Data as mean $\pm$ SD (n = 3 independent experiments; ***P < 0.001, Student's *t*-test). **D)** Synergy plot showing the most synergistic area (yellow box) between NZ-8-061 and UCN-01 in T98G cells. The Bliss synergy score is calculated over the whole dose-response matrix. **E)** Structures of two different classes of SMAPs exhibiting similar drug synergy with UCN-01. **F)** Viability of T98G cells treated SMAPs, 10 μ M DBK-794 and 5 μ M DBK-1154, alone or in combination with 25 nM UCN-01 for 72 h. Data as mean $\pm$ SD (n = 2 independent experiments; **P < 0.01, ***P < 0.001, Student's *t*-test). **G)** Caspase 3/7 activity in T98G cells treated with 8 μ M NZ-8-061 alone or in combination

with 25 nM UCN-01 (UCN) for 24 h. The caspase inhibitor Z-VAD-FMK (20 μ M) was added at the same time. Data as mean $\pm$ SD (n = 3 independent experiments; ***P < 0.001, Student's *t*-test). **H)** Representative images (left) and quantified data of colony formation assay (right) in U251, U118, A172 and U87 cells treated with 8 μ M NZ-8-061 alone or in combination with UCN-01 (UCN; 200 nM, 25 nM, 50 nM and 500 nM, respectively). Data as mean $\pm$ SD (n = 2 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001, Student's *t*-test).

Strategy for characterization of Actionable Targets of Multi-kinase Inhibitors (AToMI)

Results above demonstrate strong synergistic activity between PP2A reactivation and multi-kinase inhibition by UCN-01. However, as UCN-01 targets approximately 50 different kinases at nanomolar concentrations (10,13), it remains unclear which one(s) of these kinases are involved in SL phenotype observed in combination with PP2A reactivation. To systematically map the UCN-01 co-target interactions, we devised a functional screening platform consisting of the following steps:

- 1) Chaperone interaction assay (34) to compare direct kinase binding between UCN-01 and other STS derivatives displaying differential synergism with PP2A reactivation in GB cells.
- 2) siRNA screening for synergistic interaction between PP2A reactivation and targeting of the individual kinase hits from the step 1.
- 3) Bioinformatics analysis of actionable kinase networks based on steps 1 and 2 for identification of selective small molecule inhibitors for the critical kinase nodes in the network.
- 4) Small molecule kinase inhibitor validation experiments.

As this strategy could be generally suitable for functional filtering of targets of MKIs, we hereby refer to the screening platform as characterization of Actionable Targets of Multi-kinase Inhibitors (AToMI) (Fig. 2). The individual technologies used in AToMI are

interchangeable with the most suitable technologies for any other application AToMI would be used for.

AToMI screening for UCN-01 target kinases involved in GB cell synthetic lethality in combination with PP2A reactivation

By using AToMI, we compared the kinase target profiles of STS analogues CEP-701, K252a, and UCN-01, previously shown to induce SL in PME-1 depleted T98G cells (28), as well as K252c and Rebeccamycin that did not induce SL when combined with PP2A reactivation (28). The differential synergistic activities of these STS derivatives in combination with NZ-8-061 was confirmed by colony growth assay (Fig. S2A). All five compounds were screened for their direct kinase protein binding against 300 kinases by chaperone interaction assay (34) (Fig. 2A, S2B, Table S1). This assay measures the interaction of kinases with their chaperone Cdc37 in the presence (or absence) of kinase inhibitors. Binding of the inhibitor to its target leads to thermodynamic stabilization of the target, which can be detected as weaker interaction between the kinase and Cdc37 (35). Using log₂ -0.5-fold reduction in chaperone binding as a threshold for interaction, a total of 29 candidate kinases were identified to differentially interact with STS derivatives that synergized with PP2A (CEP-701, K252a, and UCN-01), but not with rebeccamycin or K252c (Table S2).

In the siRNA screening step of AToMI, the goal was to identify among the shared targets of CEP-701, K252a, and UCN-01, individual kinases whose co-inhibition resulted in a synergistic inhibition of cell viability with PP2A reactivation (Fig. 2B). The screen was conducted with a custom human kinase siRNA library, which had three non-overlapping siRNAs targeting each

kinases. In addition to 29 candidate kinases from the step 1, the siRNA library was extended to include 8 additional kinases frequently altered in GB (3,16) (Table S3). The siRNAs were reverse transfected to T98G cells, and cells were subsequently exposed to PP2A reactivation by NZ-8-061 treatment (Fig. 2B). In the validation screen, we included selected 25 kinases in combination with PME-1 siRNA to evaluate similarity in drug sensitization between chemical (NZ-8-061) and genetic (PME-1 siRNA) PP2A reactivation (Fig. 2B). The efficacy of PME-1 depletion by three independent siRNAs was validated by western blotting from parallel samples (Fig. S2C). For each kinase siRNA, Gene Activity Ranking Profiles and synergy scores were computed as described in the methods section of siRNA screens. Notably, regardless of the marked differences in the targeting approaches, most of the kinases targeted in both screens were found to synergize both with NZ-8-061 treatment and PME-1 depletion (Fig. 2D), validating both the shared PP2A-induced mode of action, and the broad impact of PP2A activity in kinase inhibitor tolerance in GB.

STRING protein-protein interaction network analysis of the AToMI SL kinases from the step 2 revealed enrichment of RTK/RAF/MAPK (PDGFR, RAF1, BRAF, MAPK1) and PI3K/AKT/mTOR pathways (PIKCA, AKT1, AKT3), as well as mitochondrial pyruvate dehydrogenase kinase (PDK1 and PDK4) among the kinases, connected to PP2A B-subunits, previously shown to mediate SL between STS and PME-1 depletion (Fig. 2E) (28). As each of these kinase modules were represented also among the kinases that were shared between the NZ-8-061 and siPME-1 synergy targets, we proceeded to testing these GB signaling nodes by selective small-molecule inhibitors. Selectivity of the chosen small-molecule inhibitors was evaluated based recently published target selectivity databases, and for some compounds also by Chaperone interaction assay (Table S4) (10,14). To facilitate translation of the results, we also considered

oral bioavailability and BBB permeability of the compounds in drug selection. The selected 7 kinase inhibitors were screened for cell viability effects in T98G cells with two SMAPs, NZ-8-061 and DBK-1154 (25). As a control, we used an inactive SMAP analog DBK-766, that binds PP2A but is unable to reactivate it even at a concentration of 20 μ M *in vitro* (32). The results show that both NZ-8-061 and DBK-1154 sensitized T98G cells to MK-2206 and AKT1/2i (AKT signaling) (36), and DCA (PDK1-4 inhibitor) (19,37) used at concentrations that engage their aimed target kinase (Fig. S2D, E). Importantly, the inactive SMAP (DBK-766) did not synergize with any of these kinase inhibitors (Fig. 2F). Further, RAF inhibitors (LY3009120 and Vemurafenib), PI3K inhibitor (LY294002), or MINK1 inhibitor (mubritinib) did not display significant combinatorial effect with PP2A reactivation (Fig. 2F). Importantly, another PDK inhibitor, lipoic acid (37), recapitulated the synergy with SMAPs (Fig. S3A, B). In addition, further validating the role of PP2A as a target for SMAPs in inducing the synergistic drug interaction, PP2A reactivation by PME-1 inhibition also synergized with MK-2206 and DCA treatments (Fig. S3C, D).

Collectively, these results demonstrate the usefulness of AToMI screening for identification of individual actionable target kinases for MKIs. Regarding the UCN-01 target kinases involved in SL with PP2A reactivation, AToMI screening resulted in selection of pharmacological inhibitors of AKT pathway and mitochondrial PDK1-4 kinases for further functional validation.

Figure 2. AToMI screening for UCN-01 target kinases involved in GB cell synthetic lethality in combination with PP2A reactivation. A) Heat map representation of interaction of STS derivatives, CEP-701, K252a, UCN-01, rebecamycin and K252c, with 300 protein kinases by chaperone interaction assay. Color scale bar indicates log₂ fold changes of kinase/Cdc37 interactions between inhibitor and DMSO treatments. SL - synthetic lethality, NE - no effect. **B)** Schematic illustrating of the performed kinase siRNA screens in T98G cells under NZ-8-061-

treatment or PME-1 depletion. **C)** GARP scores of siRNA screen in T98G cells under NZ-8-061-treatment or PME-1 depletion (left axis). Kinases were ordered according to synergy scores (right axis). **D)** Heat map representation of kinases involved in synthetic lethality in NZ-8-061-treated and PME-1-depleted T98G cells. Color bar indicates the synergy scores. **E)** STRING interactive mapping of screen kinase hits onto PP2A network. **F)** Viability of T98G cells and **G)** established GB, E98 and U87MG, and patient-derived GSCs, BT3-CD133⁺ and BT12, cell lines treated with the selected kinase inhibitors alone or in combination with 8 μ M NZ-8-061, 6 μ M DBK-1154 or 10 μ M DBK-766 for 72 h. Human fibroblasts were used as a negative control cell line. Data as mean $\pm$ SD (n = 3 independent experiments). *P < 0.05, **P<0.01, ***P<0.001 by Student's *t*-test.

Triplet therapy induces cytotoxicity across heterogeneous GB cell lines

Cellular heterogeneity and high intrinsic therapy resistance of glioblastoma stem-like cells (GSCs) are major challenges related GB therapies (15). Therefore, we evaluated the synergy between AKT and PDK inhibitors with SMAPs across two additional established GB cell lines, and two patient-derived mesenchymal type GSC lines (BT-CD133⁺, BT12) (25,38). Notably, western blot analysis revealed constitutive, but highly heterogeneous AKT and PDK1-4 activity across most of the brain tumor cell models used in this study (Fig. S4A). Consistently with high intrinsic kinase inhibitor resistance of GB cells (25,39), none of the kinase inhibitors as monotherapies, and used at doses that effectively inhibited their intended targets (Fig. S2D, E), did induce cytotoxic response (Fig. 2G). Further, albeit combination with SMAPs sensitized GB and GSC cells to a certain extent to AKT or PDK1-4 inhibition, the maximal co-inhibition of cell viability with double combinations was highly variable across the cell lines, and only some instances could be considered cytotoxic (Fig. 2G). Notably, the inactive SMAP analog DBK-766 did not synergize with any tested kinase inhibitor in any of the GB cell lines, and the human fibroblasts did not show any signs of synergy between kinase inhibition and SMAPs (Fig. 2G).

As these results indicate that single kinase inhibitors, even when combined with PP2A reactivation, cannot be used as a general strategy against heterogeneous GB cell populations, we decided to combine both AKT pathway and PDK1-4 inhibition together with PP2A reactivation as a triplet therapy. The rationale behind the triplet combination was that non-genetic signaling rewiring induced by single therapies (7,8) could be avoided by simultaneous targeting of two major kinase signaling nodes and by lowering the serine/threonine phosphorylation activity by PP2A. Even though both AKT inhibitors exhibited similar efficiency, we chose MK-2206 for the triplet therapy because of its frequent use in clinical trials (36). To assess long-term cytotoxic effects of the combinations, the triplet therapies were tested by using colony growth assays. Notably, fully supportive of therapy-induced therapy tolerance, all cell lines, except for T98G, were found to be resistant to cytotoxic effects of combined PDK (DCA) and AKT (MK-2206) inhibition (Fig. 3A, B). NZ-8-061 was found to potentiate effects of MK-2206 or DCA variably across the cell lines; most notably seen in E98 cells for MK-2206, and in BT3-CD133⁺ cells for DCA (Fig. 3A, B). However, the triplet therapy was the only drug combination that was found effectively eradicating all GB and GSC lines without notable effects on fibroblasts (Fig. 3A, B). This supports our hypothesis that triplet therapy is needed to tackle the heterogeneity of the therapy responses in GB.

Medulloblastoma (MB) is another brain tumor in which kinase inhibitors have been proven clinically ineffective (40). However, AKT, PDK and PP2A have all been implicated as potential targets for future MB therapies (40,41). Therefore, we studied whether the results above could be expanded from GB to MB. Reassuringly, when tested on two MB cell models, DAOY and D283-Med, representing SHH subtype and Group 3/4, respectively, we observed similar

synergistic drug interaction between MK-2206, DCA and SMAPs (NZ-8-061 and DBK-1160) as across the GB cell lines (Fig. 3C). In addition, in colony growth assay in DAOY cells, we confirmed that combination of AKT and PDK inhibition was not sufficient for potent cytotoxicity, whereas combination with SMAP DBK-1160 resulted in very potent SL phenotype (Fig. 3D).

To better understand the qualitative differences between GB cell responses to mono, double, and triplet therapies, we performed an Incucyte long-term confluency analysis in E98 cells treated with drugs twice for two weeks, with one week drug holiday in between (Fig. 3E). Although the E98 cells responded to all therapies during the first dosing period, the long-term data confirmed full resistance to each of the monotherapies. On the other hand, doublet combinations were found to be more efficient than monotherapies, but with all doublet combinations the effect was only cytostatic, as the cells were able to regain their proliferation after the drug wash-outs (Fig. 3E, see days 6-13 and 21-24). However, the triplet therapy treated cells were not able to escape the therapy during the follow-up and showed clear signs of cytotoxic response after initiation of the second dosing period (Fig. 3E, F).

Collectively, these results provide a strong validation to the AToMI screening results across genetically heterogeneous GB, GSC and MB cell lines. Importantly, the results clearly demonstrate that efficient shutdown of therapy tolerance across GB and MB cell lines requires combined inhibition of two kinases, and reactivation of PP2A phosphatase activity.

Figure 3. Triplet combination of NZ-8-061 with DCA and MK-2206 exert a synergistic cytotoxic effect in molecularly heterogeneous GB and MB cell lines. A) Representative images of colony growth assay in T98G, E98, BT3-CD133⁺, BT12 and fibroblasts under triplet combination treatment as indicated. **B)** Heat map representation of quantified colony growth assay data in the indicated cell lines treated with MK-2206 (MK; 2.5 or 5 μ M), DCA (D; 5 or 10 mM) or NZ-8-061 alone or in double or triplet combination. Human fibroblasts were used as

a negative control cell line (n=2 independent experiments). **C)** Cell viability in DAOY and D283-Med medulloblastoma cells treated with DMSO, 8 μ M DBK-116 or 10 μ M NZ-8-061 alone or in combination with 5 μ M MK-2206 (MK), 20 mM DCA, or MK + DCA for 72 h. Data as mean $\pm$ SD (n = 3 independent experiments: *P<0.05, **P<0.01, ***P<0.001 by Student's t-test). **D)** Representative images of colony growth assay in DAOY cells under triplet combination as indicated. **E)** Proliferation of E98 cells treated with DMSO, 7 μ M MK-2206 (MK), 20 mM DCA, 10 μ M NZ-8-061 (NZ) alone or in double or triplet combinations. Data as mean $\pm$ SEM (n = 6 – 12 wells per condition). *P < 0.05, **P<0.01, ***P<0.001 by Kruskal-Wallis test to DMSO group. **F)** Representative pictures of E98 cells from (E) at day 24.

The triplet therapy blunts therapy-induced signaling rewiring and potentiates apoptosis induction

Fully consistent with the therapy-induced signaling rewiring hypothesis, we found that while MK-2206 efficiently inhibited the AKT S473 phosphorylation, it simultaneously enhanced, at least to certain extent in all cell lines, phosphorylation of a direct mitochondrial PDK1-4 target PDHE1 α (Pyruvate Dehydrogenase E1 Subunit Alpha 1) (37) (Fig. 4A-C). In contrast, inhibition of PDK by DCA completely abolished phosphorylation of PDHE1 α S300, but enhanced phosphorylation of AKT in T98G cells (Fig. 4A-C). However, combination of MK-2206 and DCA was able to shut-down phosphorylation of both proteins across all cell lines (Fig. 4A-C). NZ-8-061 treatment instead affected AKT and PDK signaling in very heterogeneous manner, depending on the kinase inhibitor combination, and the cell line. In other cell lines, except for T98G, DCA + NZ-8-061 combination inhibited AKT S473 phosphorylation, but instead resulted in less efficient PDHE1 α S300 inhibition than with DCA alone (Fig. 4C). On the other hand, NZ-8-061 did rescue the compensatory PDHE1 α S300 phosphorylation induced by MK-2206. NZ-8-061 also expectedly inhibited AKT phosphorylation across the cell lines, but very interestingly also synergized with DCA in AKT inhibition (Fig. 4A-C).

To correlate these findings to the apoptotic potential of the combination therapies, we examined PARP cleavage from the same cellular lysates. The data reveals that neither NZ-8-061 at doses that synergize in drug combinations, nor total shutdown of AKT and PDK signaling (MK-2206 + DCA) (Fig. 4B, C), was alone sufficient for maximal apoptosis induction in any of the studied GB cell lines (Fig. 4D). However, the highest apoptotic response was consistently seen across all cell lines upon the triplet therapy treatment (Fig. 4D). Lastly, DAOY MB cells displayed similar therapy-induced signaling rewiring between AKT and PDK pathways than in GB cells, but combination with DBK-1160 blunted the rewiring and resulted in potent apoptosis induction (Fig. S4B).

Collectively, these observations confirm prevalent therapy-induced signaling rewiring and heterogeneity in the combinatorial drug responses across the GB cells. Importantly, SMAP treatment was found to inhibit therapy-induced signaling rewiring, and thereby convert cytostatic kinase inhibitor responses to cytotoxic effects across GB cells. The results also strongly indicate that the discovered kinase pathway inhibition tolerance mechanism is shared between GB and MB.

Figure 4. Inhibition of drug-induced signaling rewiring and apoptosis sensitization by the triplet therapy. **A)** Immunoblot assessment of phosphorylated AKT (S473), phosphorylated PDHE1 α (S300), and cleaved PARP after treatment with MK-2206 (MK), DCA or NZ-8-061 alone or in double or triplet combination for 24 h in T98G, E98, BT3-CD133⁺ and BT12 cells. Normalized quantifications from (A) for **B)** phosphorylated AKT (S473) to total AKT, **C)**

phosphorylated PDHE1 α to GAPDH, and **D**) cleaved PARP to β -actin. Data as mean $\pm$ SD (n = 3 independent experiments: *P < 0.05, **P<0.01, ***P<0.001 by Student's *t*-test).

Triplet therapy inhibits mitochondrial OXPHOS and primes to BH3 protein-mediated apoptosis

The above results revealed an interesting crosstalk between cytoplasmic AKT and mitochondrial PDK1-4 signaling. PP2A inhibition by CIP2A was recently implicated in regulation of mitochondrial oxidative phosphorylation (OXPHOS) (42). Specifically, PP2A reactivation by CIP2A inhibition resulted in inhibition of maximal mitochondrial respiration, decrease in spare oxidative capacity, and decrease in ATP production (42). To analyze whether apoptosis-sensitizing effect of pharmacological PP2A reactivation observed above would be associated with defects in OXPHOS, the T98G cells were exposed to either MK-2206 or DCA alone, or in combination with NZ-8-061, and analyzed by Seahorse Real-Time XF Analyzer (see Materials and Methods for details). As expected, DCA alone increased ATP production, as it reactivates the OXPHOS in the mitochondria (Fig. 5A, B) (37,43). On the contrary, MK-2206 reduced ATP production and mitochondrial-linked respiration (Fig. 5B). Interestingly, NZ-8-061 used at SL inducing non-toxic concentration had a broad-spectrum effect on mitochondrial metabolism. Especially interesting drug interaction was inhibition of DCA-induced OXPHOS (Basal, Maximal, and Spare), indicating that PP2A reactivation can prevent compensatory mitochondrial survival mechanism. NZ-8-061 alone, and in combination with MK-2206, also profoundly increased proton leak indicating for mitochondrial membrane damage (Fig. 5A, B).

Based on recently published results, the inner mitochondrial impairment on OXPHOS, and increased proton leakage, potentially interact with BH3-only protein mediated apoptosis regulation in the outer mitochondrial membrane (44). Therefore, we also characterized the impact of drug combinations on mitochondrial cytochrome *c* release. In line with other findings (Fig. 3C and 4D), we observed limited cytochrome *c* release by single drug treatment with NZ-8-061, DCA or MK-2206 or with double NZ-8-061 + DCA or NZ-8-061 + MK-2206 combinations (Fig. 5C). In contrast, the triplet therapy induced strong cytochrome *c* release (Fig. 5C). As cytochrome *c* release is controlled by BH3-only proteins on the outer mitochondrial membrane (45), we eventually wanted to clarify the functional interaction between cytoplasmic AKT, and mitochondrial PDK1-4 kinases on regulation of mitochondrial apoptosis by dynamic BH3 profiling. BH3 profiling uses a library of synthetic peptides to elucidate mechanisms by which cell evade apoptosis and dissect the functional relevance of each BCL2 family member (46,47). BH3 profiling revealed a limited impact on apoptotic priming by PDK1-4 inhibition, but a marked increase in the cells' susceptibility towards BIM, HRK, and MS1 mediated cytochrome *c* release when AKT was inhibited (Fig. 5D). Notably, there was a marked enhancement and broadening of BH3-mediated apoptosis priming when AKT and PDK1-4 were co-inhibited, providing an additional explanation for their synergistic pro-apoptotic effect (Fig. 5E). Results related to the impact of triplet therapy on BH3 profiling were inconclusive presumably due to high apoptotic activity (data not shown).

Collectively, these data identify multiple mitochondrial converge points between AKT, PDK1-4 and PP2A signaling. They also reveal the mechanistic basis for the high apoptotic activity of the triplet therapy due to NZ-8-061-elicited inhibition of the compensatory OXPHOS, and inner mitochondrial membrane proton leakage, combined with synergism between MK-2206

and DCA on BH3 priming. Notably, the synergistic interaction between inner mitochondrial
dysfunction (OXPHOS and proton leakage) and BH3 priming in apoptosis induction is
consistent with recent findings in other cancer types (44).

Fig. 5. Triplet therapy inhibits mitochondrial OXPHOS and primes to BH3 protein-mediated apoptosis **A)** Mitochondrial stress test Seahorse profile in T98G cells treated with 10 mM DCA or 7 μ M MK-2206 (MK) alone or in combination with 10 μ M NZ-8-061 (NZ) for 24 h. **B)** Mitochondrial parameters from (A). Data as mean $\pm$ SD (n = 3 independent experiments; *P < 0.05, **P<0.01, ***P<0.001 by Student's t-test). **C)** Cytochrome c release from T98G cells treated with 5 μ M MK-2206 (MK), 20 mM DCA or 8 μ M NZ-8-061 (NZ) alone or in double or triplet combination for 24 h. Data as mean $\pm$ SD (n = 3, *P < 0.05, **P<0.01, ***P<0.001 by Student's t-test). **D)** Priming of T98G cells to apoptosis induction by indicated BH3 peptides. 5 μ M MK-2206 (MK), 20 mM DCA were used alone or combination for 24 h. Data as mean $\pm$ SD (n = 3, *P < 0.05, **P<0.01, ***P<0.001 by Student's t-test) **E)** Schematic illustration of mitochondrial mechanisms for triplet therapy-induced apoptosis based on Fig. 4 and 5. Inhibition of PDK1-4 induces compensatory OXPHOS but this is blunted by SMAP treatment which additionally induces mitochondrial membrane proton leakage. PDK1-4 and AKT inhibition synergizes on BH3-mediated apoptosis priming and SMAP treatment inhibits signaling rewiring between the kinases. Whereas in response to doublet drug combinations cells can induce some compensatory survival mechanism, these are simultaneously inhibited in triplet therapy treated cells resulting in terminal apoptosis induction.

Validation of therapeutic potential of the triplet therapy in orthotopic GB and medulloblastoma models

In vivo relevance of the results was investigated in subcutaneous and intracranial models using both E98 GB cells and DAOY MB cells. First, we wanted to provide *in vivo* validation to AToMI screening results that the SL effects of SMAPs with UCN-01 can be recapitulated by combination of AKT and PDK inhibition. As UCN-01 does not cross the BBB, these experiments were performed using subcutaneous xenografts, and instead of NZ-8-061, we used DBK-1160 as a SMAP due to its better pharmacokinetic profile based on our previous studies (data not shown). Fully validating the results from AToMI approach, the orally dosed triplet therapy (DBK-1160 + MK-2206 + DCA) was equally efficient, or even superior to combination of DBK-1160 and UCN-01 (Fig. 6A, B). The robust *in vivo* antitumor effect of the triplet therapy in DAOY model was readily seen also when comparing the sizes of the excised tumors (Fig. 6C).

486

487 To molecularly profile the triplet therapy effect in the treated tumors, the vehicle and the
 488 triplet therapy treated tumors (n=5 for both) were subjected to mass spectrometry
 489 phosphoproteomics analysis using TMT-labeling. Upon filtering the data for those
 490 phosphopeptides there were quantifiable from at least three tumors per group, and with FDR
 491 of 5% for significance of the difference in phosphopeptide expression between the groups
 492 (Table S5), the Reactome pathway analysis validated the impact triplet therapy on both
 493 apoptosis and cell cycle, but on the other hand revealed a very strong enrichment of targets
 494 involved in “Signaling by Rho GTPases” (Fig. 6D, S5, Table S6). Furthermore, fully consistent
 495 with our model that efficient therapy response in brain tumors requires wide-spread kinase
 496 inhibition, we found inhibition of phosphorylation of several kinases from the triplet therapy
 497 treated tumors (Fig. 6E, Table S5). Notably, among those were inhibition of the
 498 phosphorylation of the activation loop of AKT1, 2 and 3, which together with enrichment of
 499 mTOR signaling based on phosphopeptide data (Fig. 6E, Table S5), perfectly supports our
 500 mechanistic data demonstrating importance of the shutdown of rewiring to AKT signaling (Fig.
 501 4). Inhibition of AKT signaling was evident also based on kinase target motif enrichment
 502 analysis where canonical AKT target motifs (R-x-R-x-x-S/T and R-x-x-S/T) were clearly enriched
 503 in the phosphopeptides downregulated by the triplet therapy (Fig. 6I). Beside AKT, among the
 504 dephosphorylated kinases were also the pro-survival downstream targets of ERK MAPK, RSK1
 505 and 3, as well as transcriptional elongation promoting kinase CDK9, that is essential for brain
 506 tumor-initiating cells (48), and a synergistic drug target with SMAPs (49). Additional
 507 exploration of the data by NetworkKIN analysis, revealed enrichment of CDK1 and CDK5 targets
 508 (Fig. S6A). CDK5 is a known neuronal kinase activated in GB and MB, and CDK1 regulation links
 509 very well to enrichment of cell cycle/mitosis based on phosphopeptide data (Fig. 6D).

Interestingly, but consistent with the therapy-induced non-genetic signaling rewiring, we also identified a number phosphopeptides upregulated in the triplet therapy treated tumors (Fig. 6F; upper right corner and Table S5). Related to kinase signaling, we noticed that several kinases involved in the pro-apoptotic JNK and p38 MAPK signaling were hyperphosphorylated in the treated tumors (Fig. S6B), and both JNK1 and JNK2 were among the top enriched kinase target motifs based on NetworkKIN analysis (Fig. S6A). As both JNK and p38 are involved apoptosis regulation by BH3 proteins (50), these data provide a plausible link between the proposed mechanism for triplet therapy induced brain tumor cell killing (Fig. 5E), and the observed *in vivo* therapeutic effects (Fig. 6F).

Finally, in intracranial model the triplet therapy was tested on luciferase-expressing E98 cells that carry characteristics of GSCs and has very infiltrative growth pattern *in vivo* (25). In addition to these faithful human GB characteristics, E98 cells displayed indistinguishable triplet therapy response as compared to patient derived GSC cell lines *in vitro* (Fig. 3). Importantly, we observed significant inhibition of tumor growth by orally dosed triplet therapy initiated upon appearance of detectable tumors at day 10 (Fig. 6G). For DAOY cells, we relied on mouse survival as the end-point measurement of the therapy effect, since no tumor growth visualization approaches were available for these tumors. Remarkably, more than 50% of the vehicle treated mice died during the therapy, whereas in the triplet therapy group only one mouse had to be sacrificed due to neurological symptoms (Fig. 6H). Following cessation of therapy after 30 days, due to local regulations, we observed a significant increase in mouse survival in the triplet therapy group, associated with 26-day prolongation of the median probability of survival (Fig 6H). No obvious toxicities were observed during triplet therapy treatment periods in either subcutaneous or intracranial models (Fig. S7). However,

as expected, the SMAP treatment resulted in reversible increase in liver weight, as has been reported earlier (32).

Collectively, the subcutaneous tumor results provide *in vivo* validation that AKT and PDK are the target kinases for the SL-inducing effect of UCN-01 in PP2A reactivated brain tumor cells. The results further validate the translational relevance of the results in independent orthotopic tumor models of common human brain tumors.

Fig. 6. Validation triplet combination therapy in vivo. A-B) Quantification of tumor volume from E98 (A) and DAOY (B) s.c. tumors in mice treated with DBK-1160 (1160; 100 mg/kg twice a day) and UCN-01 (UCN; 3 mg/kg once a day) or MK-2206 (MK; 100 mg/kg every second day) and DCA (100 mg/kg twice a day), or vehicle control. Each group had n=8 mice in E98, n=10 mice in DAOY experiments. Mean $\pm$ SD. *P < 0.05 by two-way ANOVA test. **C)** Representative images from H&E staining of DAOY s.c. tumors from (B, n=5). Scale bar, 1000 μ m. **D)** Reactome processes based on significantly (p < 0.05) regulated phosphopeptides from triplet therapy treated DAOY xenografts in (B). **E)** Kinases dephosphorylated by triplet therapy in DAOY xenografts from (B). **F)** Volcano plot showing differentially regulated phosphopeptides from (B). Icelogo kinase motif enrichment analysis from the dephosphorylated peptides (in red) (p $\leq$ 0.01, log2FC $\leq$ -0.5) revealed enrichment of canonical AKT sites (R-x-R-x-x-S/T and R-x-x-S/T). **G)** Bioluminescence follow up of an orthotopic E98 glioblastoma tumor comparing the vehicle or triplet combination therapies (DBK-1160 (100 mg/kg twice a day) + MK-2206 (100 mg/kg every second day) + DCA (100 mg/kg twice a day)). Mean $\pm$ SEM. (n=10 mice per group). **P < 0.01 by Student's t-test. **H)** Kaplan–Meier survival analysis of xenograft orthotopic DAOY model treated with triplet combination (DBK-1160 (100 mg/kg twice a day) + MK-2206 (100 mg/kg every second day) + DCA (100 mg/kg twice a day)). Vehicle n=6, Triplet combo n=8 mice per group. Mantel-Cox test. * P < 0.05.

Discussion

Kinase inhibitor resistance of brain tumors is a notable unmet clinical challenge (4,21,40). Considering that hyper activated kinase signaling is one of the hallmarks of GB (3,15), clinical resistance of GB to kinase inhibitors constitutes a mechanistic enigma. One of the potential reasons for ineffectiveness of kinase inhibitors in inhibition of oncogenic phosphorylation in GB is that phosphatases have not been taken into the account when designing the GB therapy strategies. There is a very strong theoretical basis for synergistic activities of simultaneous kinase inhibition and phosphatase activation in phosphorylation-dependent cancers (9,29), but the therapeutic impact of such combinatorial approach in overcoming therapy tolerance in brain cancers has been thus far unclear. Our results, using a panel of heterogeneous GB and MB cell lines, provide convincing proof-of-principle evidence that overcoming kinase inhibitor tolerance in brain cancers requires simultaneous multi-kinase inhibition and PP2A phosphatase activation.

MKIs provide an attractive approach to simultaneously inhibit several oncogenic kinases, and some MKIs (e.g., Sunitinib, PKC412), are clinically used as cancer therapies (12). However, similar to more selective kinase inhibitors, all tested MKIs have thus far failed in GB clinical trials (4). STS derivatives targeting more than 50 kinases (13) could provide a wide enough polypharmacological kinase inhibitor spectrum to target GB driver mechanisms, even in the case of heterogeneous GB cell populations. However, use of STSs as GB therapeutics is compromised by their inability to cross BBB. To overcome these limitations, and to better understand GB relevant STS target kinases, we developed the AToMI approach. As a result,

we found 29 kinases which selectively bound to STS derivatives and synergized with PP2A reactivation by either PME-1 inhibition or by SMAPs (Fig. 2A, S2B). Notably, the kinases which synergized with PP2A reactivation represent the commonly hyper activated pathways in GB. For example, AKT pathway is one of the most dysregulated pathways in GB, and it was well presented in the siRNA screen as depletion of AKT1, AKT3 and PIK3CA all synergized with PP2A reactivation (Fig 2C, D). Another strongly GB associated signaling mechanism was mitochondrial glycolysis, as depletion of both PDK1 and PDK4 synergized with PP2A reactivation (Fig 2C, D). PDK kinases are key regulators of metabolic shift from OXPHOS to glycolysis, which promotes GB tumor growth and resistance to therapies (18,19). However, similar to other kinase inhibitor therapies, also AKT and PDK1-4 targeting monotherapies have failed to demonstrate significant survival effects in clinical trials for GB (37,51-53). Our subsequent kinase inhibitor combination experiments, using inhibitors at doses that inhibit their target kinases, validate the ineffectiveness of AKT and PDK1-4 targeting in eradicating heterogeneous GB cell lines (Fig. 3A, B). While all double therapies tested here, involving either two kinase inhibitors, or one kinase inhibitor combined with SMAP, resulted at best in cytostatic effect, the triplet therapy induced cytotoxic response considered as clinically efficacious (Fig. 3A, B). Collectively, these results validate the usefulness of AToMI approach for future studies aiming to characterize actionable targets of MKIs in different indications. The AToMI approach also facilitated the identification of BBB permeable kinase inhibitors with similar biological activity than UCN-01. This allowed validation of all main conclusions of this study *in vivo* in two brain cancer orthotopic models displaying both significant therapeutic effect with the triplet therapy.

Phosphorylation-dependent signaling rewiring after therapy is a prevalent mechanism for cancer cells to escape apoptotic cell killing (7,8). Consistent with this model, we found that AKT inhibition by MK-2206 induced phosphorylation of the PDK1-4 target PDHE1 α in GB and MB cells (Fig. 4A-B, S4B). We also validate *in vivo* inhibition of signaling rewiring to AKT and mTOR in triplet therapy treated MB tumors (Fig. 6D-F). Notably, the therapy-induced signaling rewiring between AKT and PDK pathways was abolished when MK-2206 and DCA were combined, yet it failed to induce efficient apoptosis across the GB and MB cell lines, except for the most sensitive T98G cells (Fig. 3A-C, 4D). PP2A reactivation by SMAPs altered brain tumor cells response to MK-2206 and DCA in multiple ways. Consistent with the established role of PP2A as an AKT phosphatase (23), SMAPs reduced the basal AKT S473 phosphorylation, but surprisingly also strongly synergized with DCA in AKT dephosphorylation in most of the studied cell lines. In addition, PP2A reactivation inhibited signaling rewiring by restraining MK-2206-induced PDHE1 α S300 phosphorylation. Interaction between PP2A and PDK was also observed at the level of mitochondrial metabolism. NZ-8-061 decreased basal, spare, and maximal respiratory capacity, and blunted the DCA-induced increase in OXPHOS. Importantly, previous data indicate OXPHOS induction in response to inhibition of glycolysis (such as is seen in DCA-treated cells) as a rescue mechanism protecting cells from apoptosis (54). Furthermore, NZ-8-061 caused mitochondrial inner membrane proton leak which decreases mitochondrial membrane potential leading to higher probability of apoptosis (55).

Collectively, our data identify a strategy for killing of heterogeneous brain tumor cells based on MKI combined with PP2A reactivation. Specifically, through AToMI approach we identify AKT and PDK1-4 as the critical UCN-01 target kinases involved in synthetic lethality when combined with either genetic or pharmacological PP2A reactivation. Notably, our results are

relevant across heterogeneous GB and MB models including patient-derived GSCs. Further, PP2A activation was found to sensitize GB cells against majority of the kinases tested by the AToMI approach (Fig. 2D), hence providing a rich source for kinase inhibitor combinations to be validated in the future studies. Combined with the previously demonstrated role for PP2A in impacting lung cancer cell responses to over dozens of kinase inhibitors (24), our results indicate that the uniform kinase inhibitor resistance observed in GB and MB clinical trials (4), could be to significant extent contributed to non-genetic PP2A inhibition by its inhibitor proteins (25,28,40,56). In this regard, diagnostic definition of PP2A inhibitor protein status would greatly simplify biomarker-based analysis of PP2A activity in brain tumors because it sidesteps the need for analyzing all the possibly relevant PP2A subunits. Specifically, the current results encourage future brain tumor clinical trials with combinations of clinically tested AKT and PDK1-4 inhibitors (20,51,53) in a significant proportion of brain cancer patients with low tumor expression of PME-1 (28). Finally, our results strongly indicate that rapidly developing PP2A reactivation therapies (29) will constitute an attractive future therapy option for brain tumors when combined with multi-kinase inhibition.

Methods

Cell culture and reagents

Established human GB cell lines U87MG (gift from Ari Hinkkanen, University of Eastern Finland, Joensuu, Finland), A172, U118, U251 (gift from Pirjo Laakkonen, University of Helsinki, Helsinki, Finland), E98-FM-Cherry (gift from William Leenders, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands) and human fibroblasts (gift from Johanna Ivaska, Turku Bioscience, Turku, Finland) were cultured in DMEM (Sigma-Aldrich). T98G (VTT Technical Research Centre, Turku, Finland), DAOY (ATCC) and D283-Med (ATCC) were cultured in Eagle MEM (Sigma-Aldrich). All growth mediums were supplemented with 10% (except fibroblasts supplemented with 20%) of heat-inactivated fetal bovine serum (FBS) (Biowest), 2 mM L-glutamine and penicillin (50 U/mL)/ streptomycin (50 µg/mL). All cell cultures were maintained in a humidified atmosphere of 5% CO₂ at 37°C.

The patient-derived GSCs BT3-CD133⁺ and BT12 (Kuopio University Hospital, Kuopio, Finland) (25,38) were cultured in DMEM/F12 (Gibco) and supplemented with 2 mM L-glutamine, 2% B27-supplement (Gibco), penicillin (50 U/mL) / streptomycin (50 µg/mL), 0.01 µg/mL hFGF-β (Peprotech), 0.02 µg/mL hEGF (Peprotech) and 15 mM HEPES-buffer (Gibco). For assays requiring adherent cell, such as colony growth, GSC populations were cultured on Matrigel (Becton Dickinson) coated plates.

The following chemicals were purchased from indicated distributors: AKT1/2 inhibitor, staurosporine, CEP-701, UCN-01, PKC412, sodium salt of dichloroacetate (DCA) and lipoic acid

from Sigma-Aldrich; FRAX486 and Vemurafenib from SelleckChem; K252a and rebeccamycin from Enzo Life Sciences; K252c from Tocris Bioscience; MK-2206 from MedChemExpress. Compound were dissolved in DMSO (Sigma-Aldrich) or mQ (for DCA) and stored at -20°C. SMAPs (NZ-8-061, DBK-794, DBK-1154, DBK-1160 and DBK-766) were kindly supplied by Prof. Michael Ohlmeyer (Icahn School of Medicine at the Mount Sinai, NY, USA), were dissolved in DMSO and stored at room temperature protected from light.

Cell viability assay

Optimized numbers of cells (2.5×10^3 to 5×10^3) were plated onto 96-well plates (Perkin Elmer) and allowed to adhere. After 24 hours, cells were treated with vehicle (DMSO) or the indicated concentrations of compounds. After 72 hours, cell viability was measured using CellTiter-Glo assay (Promega) according the manufacturer's instructions using a BioTek Synergy H1 plate reader (BioTek).

Colony formation assay

Optimized numbers of cells (3×10^3 to 10×10^3) were seeded in either 12-well plates and allowed to adhere. Matrigel matrix coated plates were used for patient-derived glioma stem cells. After approximately 24 hours cells were treated with drugs. After 72 hours of incubation, drug-containing media were replaced with non-drug containing medium and incubated until the control wells were confluent. Cells were fixed with ice cold methanol and stained with 0.2% crystal violet solution in 10% ethanol for 15 min at room temperature. Plates were dried and scanned with Epson Perfection V700 Photo scanner. Quantification of

colonies were done with ImageJ by using the Colony area plugin (57). Data were normalized and presented as a per cent of the control.

Colony formation assays at hypoxic conditions were performed in InvivoO2 400 incubator (Ruskin Technology) at following conditions 1% O₂, 5% CO₂ and 90% humidity.

Caspase-3 and -7 activity assay

T98G cells (2.5 x 10³) were plated in 96-well plates (Perkin Elmer) and allowed to adhere. After 24 hours, cells were treated with drugs for the next 24 hours. Pan-caspase inhibitor Z-VAD-FMK (10 mM, Promega) was added at the same time as drugs. Caspase-3 and -7 activity was measured by Caspase-Glo 3/7 Assay (Promega) according the manufacturer's instructions using a BioTek Synergy H1 plate reader.

Western blotting and antibodies

Standard immunoblotting analysis was performed using the following primary antibodies: AKT (Cell Signaling, 9272S, 1:1,000), phospho Akt S473 (Cell Signaling, 9271, 1:1,000), PME-1 (Santa Cruz, sc-20086, 1:1,000), β-actin (Sigma-Aldrich, A1978, 1:10,000), phospho PDHE1-A type I (S300) (Millipore, ABS194, 1:1,000), cleaved PARP1 (E51) (Abcam, ab32064, 1:1,000) and GAPDH (Hytest, 5G4cc, 1:10,000). Secondary antibodies were purchased from LI-COR, mouse (926-32212) and rabbit (926-68021). The membranes were scanned using an Odyssey scanner (Li-Cor Biosciences). Quantification of protein abundance was assessed with Image Studio Lite (version 5.2) on three immunoblots from independent lysates.

Chaperone binding assay

LUMIER (LUminescence-based Mammalian IntERactome) with BACON (bait control) assay was performed as previously described (35). In short, 3xFLAG-tagged bait proteins are transfected into 293T cells expressing the Chaperone-Renilla (prey) luciferase in a 96-well plate. After two days, cells are treated with kinase inhibitors (or DMSO) for 1 hour before cell lysis. The cell lysates expressing each bait protein are applied to anti-FLAG coated 384-well plates, which captures the bait protein. The amount of luminescence in the well, after washing off nonspecifically binding proteins, indicates the interaction between the bait protein with the prey protein. After the luminescence measurement, the amount of bait protein is measured with ELISA, using a different, polyclonal anti-FLAG antibody conjugated to horseradish peroxidase.

Long-term growth assay

E98 cells (3×10^3) were plated into 96-well plate. On the next day cells were treated with DMSO, MK-2206 (7 μ M), DCA (20 mM), NZ-8-061 (10 μ M) alone, or in their double or triplet combinations (6-12 wells/condition). Every 3-4 days medium was replaced with fresh media with or without drugs. The confluency of the wells was determined daily using IncuCyte ZOOM live cell analysis system (Essen Bioscience).

Mitochondrial respiration measurement

Agilent Seahorse XF Cell Mito Stress Test (Agilent Seahorse Bioscience) was applied to T98G cells according the manufacturer's instructions. In short, T98G cells were seeded at 1×10^4 cells per well in a Seahorse 96-well XF Cell Culture microplate in 100 μ L of the growing medium. On the next day cells were treated with DMSO, DCA (10 mM), MK-2206 (7 μ M) alone or in combination with NZ-8-061 (10 μ M) for the next 24 hours. On the day of analysis, the

growth media were replaced with 120 μ L of XF assay media (non-buffered DMEM supplemented with 10 mM glucose, 1 mM sodium pyruvate and 2 mM glutamine) and incubated at 37°C in a non-CO₂ incubator for one hour before running assay. Mitochondrial function of the cells was analyzed by sequential injections of modulators, oligomycin, carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP), and rotenone/antimycin A, at Seahorse XFe96 analyzer (Agilent Seahorse Bioscience). The Seahorse XF Mito Stress Test Report Generator was used to calculate the Seahorse XF Cell Mito Stress Test parameters from Wave software (version 2.6.153). The data were normalized to total protein per well using BCA assay (Thermo Fisher Scientific).

BH3 profiling

BH3 profiling was performed as previously described (46,47). In brief, T98G cells were pretreated with DMSO, MK-2206 (5 μ M), DCA (20 mM), NZ-8-061 (8 μ M) alone, or in their double or triplet combinations for 24 hours. On the next day, cells were permeabilized with 0.002% digitonin and treated with a library of synthetic peptides. Peptides used were BIM at 0.01 μ M, BAD, HRK and MS1 at 10 μ M. The BIM peptide assesses the functionality of BAX and BAK. BAD binds and antagonizes BCL-2, BCL-xL, BCL-W, and BFL-1. HRK specifically binds and antagonizes BCL-xL. MS1 binds and antagonizes MCL-1. A pore-forming peptide, alamethicin (positive control), or DMSO (negative control) served as controls. Cells were incubated with the peptides for half an hour at 25°C and subsequently fixed with 4% paraformaldehyde for 10 min. Finally, intracellular cytochrome c was stained with an immunofluorescence-labeled antibody (BioLegend Alexa Fluor 647 anti-Cytochrome c Antibody, clone 6H2.B4). Relative cytochrome c release was assessed by formula $1 - [(sample-pos.ctrl.)/(neg.ctrl.-pos.ctrl.)]$.

Bioinformatics analysis

Cytoscape network analysis software (version 3.9.0) (58) was used to visualize the STRING interactive map of hit kinases (59). For calculation and visualization of synergy scores, dose-response matrix of NZ-8-061 and UCN-01 combination data were applied to SynergyFinder (version 2.0) web-application (60).

Statistical analyses

For cell culture experiments, three biological replicates have been performed, and each condition was tested in triplicate, unless otherwise specified. Data are presented as mean $\pm$ SD and statistical analyses were carried out using a two-tailed Student's t-test assuming unequal variances. For *in vivo* experiments, the following statistical tests were chosen depending on the results of the preliminary Shapiro-Wilk test of data normality. Two way ANOVA with Tukey's multiple comparisons test were used to assess differences between three or more experimental groups. Log-rank (Mantel-Cox) test was used in survival analysis. These univariate statistical analyses were performed using GraphPad Prism 9 software (GraphPad Software). $P < 0.05$ was considered statistically significant.

Supplementary Materials

Supplementary Methods and Figures S1-7.
Table S1. Chaperone interaction assay data.
Table S2. 28 kinase hit list.
Table S3. The customer kinase siRNA library.
Table S4. Inhibitor selectivity data.

Table S5. Significantly ($p < 0.05$) regulated phosphopeptides from triplet therapy treated DAOY xenografts.

Table S6. Enriched Reactome pathways based on Table S5.

Table S7. The list of the used siRNA.

Competing interests

Authors declare no competing interests.

Authors' Contributions

Conception and design: O.V.D., J.M., A.K. J.W. Development of methodology: O.V.D., J.M., R.H., X.Q., J.W. Experimental work: M.T., O.V.D., C.S-F., K.W. R.K., M.P., O.K. Bioinformatic analysis: M.J., L.Y., O.K., T.A. In vivo work: O.V.D., J.M., R.H. Resources: M.O. Writing: O.V.D., J.M., T.A., J.W.

Acknowledgements

Authors want to acknowledge Turku Center for Disease Modelling (TCDM) and Made Consulting for expert help with mouse experiments, Artur Padzic for help and expertise with lentivirus experiments, William Eccleshall and Mung Kwan Long for help with Seahorse experiments, and Kari Kurppa for expert help with Incucyte experiments and for helpful discussions. Johanna Ivaska is thanked for comments on the manuscript. Taina Kalevo-Mattila is acknowledged for excellent technical support as well as the entire Turku Bioscience personnel for excellent working environment.

810 **Funding**

811 Project was funded by Jane and Aatos Erkko Foundation, Finnish Cultural Foundation, Sigrid
 812 Juselius Foundation, K.Albin Johanssons Foundation, AAMU Suomen Lasten Syöpäsäätiö,
 813 Turku Doctoral Programme of Molecular Medicine, Academy of Finland, and Finnish Cancer
 814 Foundation.

References

1. Cohen P, Cross D, Janne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. *Nat Rev Drug Discov* **2021**;20(7):551-69 doi 10.1038/s41573-021-00195-4.
2. Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schioth HB. Trends in kinase drug discovery: targets, indications and inhibitor design. *Nat Rev Drug Discov* **2021**;20(11):839-61 doi 10.1038/s41573-021-00252-y.
3. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, *et al.* The somatic genomic landscape of glioblastoma. *Cell* **2013**;155(2):462-77 doi 10.1016/j.cell.2013.09.034.
4. Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, Choulier L. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. *Cancers (Basel)* **2021**;13(8) doi 10.3390/cancers13081795.
5. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, *et al.* Emerging insights into the molecular and cellular basis of glioblastoma. *Genes Dev* **2012**;26(8):756-84 doi 10.1101/gad.187922.112.
6. Shen S, Vagner S, Robert C. Persistent Cancer Cells: The Deadly Survivors. *Cell* **2020**;183(4):860-74 doi 10.1016/j.cell.2020.10.027.
7. Konieczkowski DJ, Johannessen CM, Garraway LA. A Convergence-Based Framework for Cancer Drug Resistance. *Cancer Cell* **2018**;33(5):801-15 doi 10.1016/j.ccell.2018.03.025.

8. Smith MP, Wellbrock C. Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance. Clin Cancer Res **2016**;22(24):5966-70 doi 10.1158/1078-0432.CCR-16-0954.
9. Westermarck J. Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back. FEBS J **2018**;285(22):4139-45 doi 10.1111/febs.14617.
10. Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, *et al.* The target landscape of clinical kinase drugs. Science **2017**;358(6367) doi 10.1126/science.aan4368.
11. Lin A, Giuliano CJ, Palladino A, John KM, Abramowicz C, Yuan ML, *et al.* Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Science translational medicine **2019**;11(509) doi 10.1126/scitranslmed.aaw8412.
12. Montoya S, Soong D, Nguyen N, Affer M, Munamarty SP, Taylor J. Targeted Therapies in Cancer: To Be or Not to Be, Selective. Biomedicines **2021**;9(11) doi 10.3390/biomedicines9111591.
13. Gani OA, Engh RA. Protein kinase inhibition of clinically important staurosporine analogues. Natural product reports **2010**;27(4):489-98 doi 10.1039/b923848b.
14. Tang J, Tanoli ZUR, Ravikumar B, Alam Z, Rebane A, Vaha-Koskela M, *et al.* Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions. Cell Chem Biol **2018**;25(2):224-+ doi 10.1016/j.chembiol.2017.11.009.
15. Gimple RC, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev **2019**;33(11-12):591-609 doi 10.1101/gad.324301.119.

16. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, *et al.* Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science* **2014**;344(6190):1396-401 doi 10.1126/science.1254257.
17. Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. *Nature Reviews Cancer* **2020**;20(2):74-88 doi 10.1038/s41568-019-0216-7.
18. Agnihotri S, Zadeh G. Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions. *Neuro-oncology* **2016**;18(2):160-72 doi 10.1093/neuonc/nov125.
19. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, *et al.* Metabolic modulation of glioblastoma with dichloroacetate. *Science translational medicine* **2010**;2(31):31ra4 doi 10.1126/scitranslmed.3000677.
20. Wang Z, Peet NP, Zhang P, Jiang Y, Rong L. Current Development of Glioblastoma Therapeutic Agents. *Molecular cancer therapeutics* **2021**;20(9):1521-32 doi 10.1158/1535-7163.MCT-21-0159.
21. Alexandru O, Horescu C, Sevastre AS, Cioc CE, Baloi C, Oprita A, *et al.* Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches. *Contemp Oncol (Pozn)* **2020**;24(1):55-66 doi 10.5114/wo.2020.94726.
22. Kauko O, Westermarck J. Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer. *Int J Biochem Cell Biol* **2018**;96:157-64 doi 10.1016/j.biocel.2018.01.005.
23. Fowle H, Zhao Z, Grana X. PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer. *Adv Cancer Res* **2019**;144:55-93 doi 10.1016/bs.acr.2019.03.009.

24. Kauko O, O'Connor CM, Kuleskiy E, Sangodkar J, Aakula A, Izadmehr S, *et al.* PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. *Science translational medicine* **2018**;10(450) doi 10.1126/scitranslmed.aag1093.
25. Merisaari J, Denisova OV, Doroszko M, Le Joncour V, Johansson P, Leenders WPJ, *et al.* Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma. *Brain Communications* **2020**;2(1) doi ARTN 02 10.1093/braincomms/fcaa002.
26. Qin S, Li J, Si Y, He Z, Zhang T, Wang D, *et al.* Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme. *Mol Carcinog* **2018**;57(6):687-99 doi 10.1002/mc.22789.
27. Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, Teittinen K, *et al.* PME-1 Protects Extracellular Signal-Regulated Kinase Pathway Activity from Protein Phosphatase 2A-Mediated Inactivation in Human Malignant Glioma. *Cancer Research* **2009**;69(7):2870-7 doi 10.1158/0008-5472.Can-08-2760.
28. Kaur A, Denisova OV, Qiao X, Jumppanen M, Peuhu E, Ahmed SU, *et al.* PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells. *Cancer Research* **2016**;76(23):7001-11 doi 10.1158/0008-5472.Can-16-1134.
29. Vainonen JP, Momeny M, Westermarck J. Druggable cancer phosphatases. *Science translational medicine* **2021**;13(588) doi 10.1126/scitranslmed.abe2967.
30. Akimov Y, Aittokallio T. Re-defining synthetic lethality by phenotypic profiling for precision oncology. *Cell Chem Biol* **2021**;28(3):246-56 doi 10.1016/j.chembiol.2021.01.026.

31. Kaur A, Westermarck J. Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1. *Biochem Soc Trans* **2016**;44(6):1683-93 doi 10.1042/BST20160161.
32. Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, *et al.* Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. *J Clin Invest* **2017**;127(6):2081-90 doi 10.1172/JCI89548.
33. Vit G, Duro J, Rajendraprasad G, Hertz EPT, Kauffeldt Holland LK, Weisser MB, *et al.* Cellular toxicity of iHAP1 and DT-061 does not occur through PP2A-B56 targeting. *bioRxiv* **2021**:2021.07.08.451586 doi 10.1101/2021.07.08.451586.
34. Taipale M. Quantitative Profiling of Chaperone/Client Interactions with LUMIER Assay. *Methods Mol Biol* **2018**;1709:47-58 doi 10.1007/978-1-4939-7477-1_4.
35. Taipale M, Krykbaeva I, Whitesell L, Santagata S, Zhang J, Liu Q, *et al.* Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. *Nature biotechnology* **2013**;31(7):630-7 doi 10.1038/nbt.2620.
36. Shariati M, Meric-Bernstam F. Targeting AKT for cancer therapy. *Expert Opin Investig Drugs* **2019**;28(11):977-88 doi 10.1080/13543784.2019.1676726.
37. Stacpoole PW. Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer. *Journal of the National Cancer Institute* **2017**;109(11) doi 10.1093/jnci/djx071.
38. Le Joncour V, Filppu P, Hyvonen M, Holopainen M, Turunen SP, Sihto H, *et al.* Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization. *EMBO Mol Med* **2019**;11(6) doi 10.15252/emmm.201809034.

39. Mooney J, Bernstock JD, Ilyas A, Ibrahim A, Yamashita D, Markert JM, *et al.* Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma. *World Neurosurg* **2019**;129:90-100 doi 10.1016/j.wneu.2019.05.205.
40. Wen J, Hadden MK. Medulloblastoma drugs in development: Current leads, trials and drawbacks. *Eur J Med Chem* **2021**;215:113268 doi 10.1016/j.ejmech.2021.113268.
41. Di Magno L, Manzi D, D'Amico D, Coni S, Macone A, Infante P, *et al.* Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth. *Cell Cycle* **2014**;13(21):3404-13 doi 10.4161/15384101.2014.952973.
42. Austin JA, Jenkins RE, Austin GM, Glenn MA, Dunn K, Scott L, *et al.* Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5' AMP-activated protein kinase signalling in malignant cells. *Biochem J* **2019**;476(15):2255-69 doi 10.1042/BCJ20190121.
43. Atas E, Oberhuber M, Kenner L. The Implications of PDK1-4 on Tumor Energy Metabolism, Aggressiveness and Therapy Resistance. *Frontiers in oncology* **2020**;10:583217 doi 10.3389/fonc.2020.583217.
44. Bosc C, Saland E, Bousard A, Gadaud G, Sabatier M, Cognet G, *et al.* Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. *Nature Cancer* **2021**;2:1204–23.
45. Potter DS, Letai A. To Prime, or Not to Prime: That Is the Question. *Cold Spring Harbor symposia on quantitative biology* **2016**;81:131-40 doi 10.1101/sqb.2016.81.030841.
46. Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, *et al.* Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. *Blood* **2019**;133(6):566-75 doi 10.1182/blood-2018-07-865527.

47. Ryan J, Montero J, Rocco J, Letai A. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. *Biol Chem* **2016**;397(7):671-8 doi 10.1515/hsz-2016-0107.
48. Xie Q, Wu Q, Kim L, Miller TE, Liau BB, Mack SC, *et al.* RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation. *J Clin Invest* **2016**;126(7):2757-72 doi 10.1172/JCI86114.
49. Vervoort SJ, Welsh SA, Devlin JR, Barbieri E, Knight DA, Offley S, *et al.* The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. *Cell* **2021**;184(12):3143-62 e32 doi 10.1016/j.cell.2021.04.022.
50. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. *Oncogene* **2008**;27(48):6245-51 doi 10.1038/onc.2008.301.
51. Kaley TJ, Panageas KS, Mellinghoff IK, Nolan C, Gavrilovic IT, DeAngelis LM, *et al.* Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. *J Neurooncol* **2019**;144(2):403-7 doi 10.1007/s11060-019-03243-7.
52. Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, *et al.* Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. *J Clin Oncol* **2019**;37(9):741-50 doi 10.1200/JCO.18.01207.
53. Dunbar EM, Coats BS, Shroads AL, Langaee T, Lew A, Forder JR, *et al.* Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. *Investigational new drugs* **2014**;32(3):452-64 doi 10.1007/s10637-013-0047-4.
54. Oshima N, Ishida R, Kishimoto S, Beebe K, Brender JR, Yamamoto K, *et al.* Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and

- Vulnerability to Combination Therapy. Cell reports **2020**;30(6):1798-810 e4 doi 10.1016/j.celrep.2020.01.039.
55. Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential ($\Delta\psi(m)$) in apoptosis; an update. Apoptosis **2003**;8(2):115-28 doi 10.1023/a:1022945107762.
56. Garner EF, Williams AP, Stafman LL, Aye JM, Mroczek-Musulman E, Moore BP, *et al.* FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Scientific reports **2018**;8(1):6913 doi 10.1038/s41598-018-25263-5.
57. Guzman C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PloS one **2014**;9(3):e92444 doi 10.1371/journal.pone.0092444.
58. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research **2003**;13(11):2498-504.
59. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, *et al.* The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res **2021**;49(D1):D605-D12 doi 10.1093/nar/gkaa1074.
60. Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res **2020**;48(W1):W488-W93 doi 10.1093/nar/gkaa216.